MIRA · Mira Pharmaceuticals, Inc.
$0.75
-0.02 (-2.60%)
At close · Aug 28
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“We do not have sufficient cash and cash equivalents as of the date of filing this Quarterly Report on Form 10-Q to support our operations for at least the 12 months following the date the financial statements are issued. These conditions raise substantial doubt about our ability to continue as a going concern through 12 months after the date that the financial statements are issued.”View the 10-Q filed Aug 12, 2026
Market Cap
$31.52M
Shares
42.02M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.75
Open$0.75
Day$0.75–0.78
52W close$0.61–1.80
Avg vol 30d82K
Short int211K · 0.5% float · 1.5d
Short vol9%
DataAug 2023–Aug 2026
Filing10-Q · Aug 12
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 12, 2026
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Neutral
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 14.4 · calm
Equity put/call 0.62
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−33%
below
Price vs 50-day avg
−11%
below
RSI (14)
45
neutral
MACD trend
Positive
52-week position
11%
near low
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
1-month return
−5%
trailing
6-month return
−35%
trailing
YTD return
−50%
this year
Relative strength
−49%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Flat
0% holders QoQ · +4 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.50% of float · ▲ +2.8% MoM · 1.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
26 holders — mid 3-yr range
Squeeze score
46
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
78%
annualized · 1-yr
Max drawdown
−66%
past year
ATR
7.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−33%
Bearish
Price vs 50-day avg
−11%
Bearish
RSI (14)
45
Neutral
MACD trend
Positive
Bullish
52-week position
11%
Bearish
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Bearish · 1 of 6
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Flat
0% holders QoQ · +4 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.50% of float · ▲ +2.8% MoM · 1.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
26 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1
Now $1 · 11%
Range high $2
vs 200-day avg -33%
vs 50-day avg -11%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Drug Manufacturers - General — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MIRA
this stock
Mira Pharmaceuticals, Inc.
|
$31.52M | -50.3% | — | — | 0.5% |
|
LLY
ELI LILLY & Co
|
$1.11T | +9.3% | +44.7% | 39.4 | 0.7% |
|
JNJ
Johnson & Johnson
|
$645.95B | +29.5% | +6.0% | 31.1 | 0.9% |
|
ABBV
AbbVie Inc.
|
$451.46B | +11.8% | +8.6% | 72.2 | 1.0% |
|
MRK
Merck & Co., Inc.
|
$366.00B | +40.9% | +1.3% | 119.6 | 1.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MIRA | -1.8% | -5.3% | -35.3% | -5.3% | -50.3% |
| SPY | +0.5% | +3.0% | +13.4% | +3.0% | +12.8% |
| vs SPY | -2.2% | -8.3% | -48.8% | -8.3% | -63.1% |